Discover how the shift to a rebate model in the 340B Drug Pricing Program could impact cash flow for hospitals and clinics.

This white paper from IQVIA’s Market Access Technology Solutions team presents data-driven models comparing eight drug inventory and rebate scenarios, including the new HRSA rebate pilot, to quantify financing (interest) costs for covered entities. The analysis finds that, even under conservative assumptions, interest costs associated with the rebate model are minimal, less than half a percent of drug list price, and unlikely to pose a financial barrier.

With clear explanations of discount mechanisms, inventory models, and sensitivity analyses, this white paper offers essential insights for policy makers, manufacturers, and healthcare providers navigating the evolving 340B landscape.